Multiplex giant magnetoresistive biosensor microarrays identify interferon-associated autoantibodies in systemic lupus erythematosus. by Lee, Jung-Rok et al.
UC San Diego
UC San Diego Previously Published Works
Title
Multiplex giant magnetoresistive biosensor microarrays identify interferon-associated 
autoantibodies in systemic lupus erythematosus.
Permalink
https://escholarship.org/uc/item/4dd748ws
Journal
Scientific reports, 6(1)
ISSN
2045-2322
Authors
Lee, Jung-Rok
Haddon, D James
Wand, Hannah E
et al.
Publication Date
2016-06-09
DOI
10.1038/srep27623
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1Scientific RepoRts | 6:27623 | DOI: 10.1038/srep27623
www.nature.com/scientificreports
Multiplex giant magnetoresistive 
biosensor microarrays identify  
interferon-associated autoantibodies 
in systemic lupus erythematosus
Jung-Rok Lee1,*, D. James Haddon2,*, Hannah E. Wand2, Jordan V. Price3, Vivian K. Diep2, 
Drew A. Hall4, Michelle Petri5, Emily C. Baechler6, Imelda M. Balboni7, Paul J. Utz2,8 & 
Shan X. Wang9,10
High titer, class-switched autoantibodies are a hallmark of systemic lupus erythematosus (SLE). 
Dysregulation of the interferon (IFN) pathway is observed in individuals with active SLE, although the 
association of specific autoantibodies with chemokine score, a combined measurement of three IFN-
regulated chemokines, is not known. To identify autoantibodies associated with chemokine score, we 
developed giant magnetoresistive (GMR) biosensor microarrays, which allow the parallel measurement 
of multiple serum antibodies to autoantigens and peptides. We used the microarrays to analyze serum 
samples from SLE patients and found individuals with high chemokine scores had significantly greater 
reactivity to 13 autoantigens than individuals with low chemokine scores. Our findings demonstrate 
that multiple autoantibodies, including antibodies to U1-70K and modified histone H2B tails, are 
associated with IFN dysregulation in SLE. Further, they show the microarrays are capable of identifying 
autoantibodies associated with relevant clinical manifestations of SLE, with potential for use as 
biomarkers in clinical practice.
Systemic lupus erythematous (SLE) is a chronic, inflammatory autoimmune disease that affects multiple organ 
systems, with an estimated prevalence of 300,000 people in the United States1. The manifestations of SLE are 
heterogeneous, making it a difficult disease to manage clinically. Further, SLE has an unpredictable course, with 
periods of flares and remission. A hallmark of SLE is the presence of high titer, class-switched antibodies that 
bind nuclear antigens, including DNA, ribonucleoprotein (RNP), Smith, Ro, La, and histones2,3. Gene expres-
sion microarray analysis of the peripheral blood mononuclear cells (PBMCs) of individuals with SLE has shown 
that the interferon (IFN) pathway is dysregulated in a subset of individuals who have more severe disease4. 
Subsequently, the chemokine score, based on serum levels of three interferon-regulated chemokines, was found 
to be positively correlated with the interferon signature, disease activity, and likelihood of flare5,6. Identification 
of autoantibodies that are associated with elevated chemokine scores could increase our understanding of the 
mechanisms leading to dysregulation of the IFN pathway in SLE, and the causes of disease flares.
At least 180 autoantigens have been described in SLE7. However, current clinical tests typically only meas-
ure levels of a single autoantibody, potentially missing much of the clinical heterogeneity of SLE. Autoantigen 
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microarrays have the advantage of profiling hundreds of autoantibodies in parallel, but typically take multiple 
days to perform8. Giant magnetoresistive (GMR) biosensors are microscopic electrical sensors that can detect 
local magnetic field changes induced by the presence of magnetic nanoparticles (MNPs) in their proxim-
ity9–12. Recently, our group developed multiplexed assays for protein biomarkers by coating GMR biosensors 
with capture antibodies and MNPs with detection antibodies9,13,14. The GMR biosensors were highly sensitive, 
had a large dynamic range (> 4 decades)9, and allowed for the real-time measurement of antibody binding15. 
Real-time measurement has the added benefit of making GMR biosensor assays faster to perform than traditional 
fluorescence-based microarrays. To date, GMR biosensors have not been applied to the multiplexed detection of 
autoantibodies.
In this study, we developed GMR biosensor microarrays for the multiplexed measurement of antibodies to 
known autoantigens, including post-translationally modified (PTM) peptides. We used the GMR biosensor 
autoantigen microarrays to identify autoantibodies that were significantly associated with elevated chemokine 
scores in individuals with SLE. Elucidating the relationship between autoantibodies and dysregulation of the IFN 
pathway may provide new insights into SLE pathogenesis, and enable rapid monitoring of disease activity.
Results
Development and validation of GMR biosensor autoantigen microarrays. To investigate the 
application of GMR biosensor technology to the multiplexed measurement of autoantibodies, we designed and 
fabricated GMR biosensor microarray chips, each with 72 effective sensors, as the platform for autoantigen 
microarrays (Fig. 1a). We used a non-contact robotic microarrayer to print known SLE autoantigens (histones 
H2A and H4, H2B, and H3, Ribo P, dsDNA, U1-70K, Ro52, Ro60, La/SSB, and Smith) on the surface of the chips’ 
GMR biosensors. We also printed known antigenic peptides derived from the histone H2B N-terminal tail and 
the RNA-binding domain of U1-70K (as well as FLAG peptide controls). More detailed information about the 
selected autoantigens and peptides is presented in Supplementary Tables 1 and 2. A schematic of the analysis of 
antibody-containing samples using GMR biosensor autoantigen microarrays is shown in Fig. 1b.
To validate the GMR biosensor autoantigen microarrays, we started by performing a titration of a monoclonal 
antibody to the FLAG epitope (M2 clone). We found that anti-FLAG was highly specific to the FLAG octapeptide, 
and did not bind to any of the FLAG point mutants immobilized on the biosensors of the microarrays (Fig. 2a). 
The GMR microarrays had dynamic ranges and detection limits that were comparable to peptide ELISA per-
formed with the same antibody and FLAG peptides (Supplementary Figure 1a). Next, we tested the microarrays 
using monoclonal and polyclonal antibodies to Ro52 and U1-70K, respectively. We found that both antibodies 
bound to their target antigens, but not to other proteins or dsDNA immobilized on the surface of the microarray 
(Fig. 2b,c). We also found that the polyclonal U1-70K antibody was reactive to sequences within the RNA-binding 
domain of U1-70K (Fig. 2d), which were previously reported by our group16. These results demonstrate that the 
GMR biosensor autoantigen microarrays are capable of sensitive and specific detection of the reactivity of mono-
clonal and polyclonal antibodies to protein and peptide antigens. In addition, we found that the intrinsic charge of 
MNPs does not influence detection of serum antibodies to charged antigens compared to ELISA (Supplementary 
Figure 2).
To investigate whether GMR biosensor autoantigen microarrays could be used to measure antibodies to 
post-translationally modified autoantigens, we probed the microarrays with monoclonal antibodies specific 
to acetylated forms (K5Ac and K20Ac) of the histone H2B N-terminal tail. The GMR biosensor autoantigen 
microarrays showed high levels of binding of anti-K5Ac to the two K5Ac modified H2B peptides (H2B 1-20 
AllAc and H2B 2-21 AllAc), but not to unmodified and mutated H2B peptides (Fig. 2e). Similarly, anti-K20Ac 
showed high levels of specific reactivity to the three K20Ac-modified H2B peptides (H2B 1-20 AllAc, H2B 2-21 
AllAc and H2B 11-21 AllAc), but not unmodified and mutated H2B peptides (Fig. 2f). Removal of the proline at 
the N-terminus or the alanine at the C-terminus reduced binding of anti-K5Ac and anti-H2B K20Ac, respectively 
(Fig. 2e,f). We performed ELISA with the same antibodies and H2B peptides for comparison, and found ELISA 
had a higher level of non-specific binding to unmodified peptides than was observed with the GMR microarrays 
(Supplementary Figure 3). These results demonstrate that the GMR biosensor autoantigen microarrays can be 
used to measure PTM-specific antibodies, and define the critical residues in their consensus binding sequences.
GMR biosensor autoantigen microarrays identify autoantibodies associated with dysregula-
tion of the IFN pathway in SLE. Dysregulation of the IFN pathway is thought to play a central role in SLE. 
Chemokine scores, based on the serum levels of three IFN-regulated chemokines, are associated with SLE, disease 
activity, and likelihood of flare5. Knowledge of whether specific autoantibodies are associated with chemokine 
scores could help clarify the mechanisms leading to dysregulation of the IFN pathway and disease flares in SLE. 
To identify autoantibodies associated with dysregulation of the IFN pathway, we used GMR biosensor autoan-
tigen microarrays to compare serum samples from 15 SLE patients who had high chemokine scores with 15 
SLE patients who had low chemokine scores (Table 1). Chemokine scores were based on serum levels of three 
IFN-regulated chemokines: MCP1 (Monocyte chemotactic protein 1, CCL2), IP10 (Interferon gamma-induced 
protein 10, CXCL10), and MIP3β (Macrophage inflammatory protein-3-beta, CCL19)6. Ten healthy samples were 
measured in parallel as controls. For the analysis of patient serum, we modified our method for printing peptide 
antigens to a two-step process, where we printed streptavidin on each biosensor prior to printing biotinylated 
peptides (Supplementary Figure 4). We found results from this approach had a higher level of agreement with 
peptide ELISA, compared to direct spotting of peptides (Supplementary Figure 5). To avoid the possibility of 
anti-human IgG biotinylated antibodies directly binding to the streptavidin on the surface of the microarrays, we 
used Protein G-coated MNPs to detect antibody-peptide binding instead17. Overall, the GMR biosensor autoan-
tigen microarrays had a high level of agreement with traditional fluorescence-based autoantigen microarrays and 
clinical tests (Supplementary Figure 6).
www.nature.com/scientificreports/
3Scientific RepoRts | 6:27623 | DOI: 10.1038/srep27623
The Significance Analysis of Microarrays (SAM)18 algorithm was used to identify statistically significant dif-
ferences in autoantigen reactivity between the high and low chemokine score groups. SAM accounts for the large 
number of comparisons inherent in microarray analyses by using repeated random permutations of the data to 
Figure 1. GMR biosensor autoantigen microarrays. (a) Optical images of a GMR biosensor chip and a 
cartridge with a reaction well (left). The sensor chip measures 10 × 12 mm and consists of an array of 8 × 10 
sensors (total 80 sensors). Each sensor size is 100 × 100 μ m (right). (b) A schematic of assaying antibody reactivity 
to autoantigens (not to scale). (1) Autoantigens were printed on the surface of the chip’s sensors. (2) The sample 
was added to the reaction well, allowing antibodies to bind to their corresponding antigens. (3) After washing, 
species-specific, biotinylated anti-IgG antibodies were used as a secondary reagent. (4) Streptavidin-coated MNPs 
bind to the biotinylated detection antibodies, and the respective sensor detects stray field from the bound MNPs.
www.nature.com/scientificreports/
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estimate the false discovery rate (FDR). SAM identified 14 autoantigens with significantly greater reactivity in SLE 
patients with high chemokine scores than low chemokine scores (Fig. 3), including dsDNA, which had previously 
been associated with high chemokine scores by Bauer et al.6. A citrullinated vimentin peptide was found to be 
significant by SAM, but reactivity levels to the peptide were very low and the most reactive sample was from an 
Figure 2. Validation of GMR biosensor autoantigen microarrays with commercial antibodies, including 
PTM-specific antibodies. Serial dilutions of monoclonal antibodies to (a) FLAG, (b) Ro52, (e) H2B K5Ac, and 
(f) H2B K20Ac, as well as polyclonal antibodies to (c,d) U1-70K, were used to probe individual GMR biosensor 
autoantigen microarrays printed with the cognate antigens and controls. The target epitopes K5Ac and K20Ac, 
are indicated in red in (e,f) respectively. Each data point is the average of signals from four replicate sensors on 
the microarray, and error bars represent standard deviations. The concentration of anti-H2B K20Ac was not 
provided by the manufacturer, and is presented as a relative concentration to the stock solution.
Variable Chemokine high Chemokine low p-value
Age at sample, median (range) years 36 (22–62) 42.5 (29–61) 0.2262
Sampling date, post-diagnosis, median 
(range) years 8 (0–26) 7 (2–23) 0.4433
Number (%) females 15 (100) 15 (100) 1#
ANA titer 960 (160–20480) 320 (40–1280) 0.0025
dsDNA antibody positive patients (%) 15 (100) 3 (21) < 0.0001#
SLEDAI, median (range) 6 (0–16) 0 (0–8) 0.0006
Asian/Pacific Islander (%) 1 (7) 0 (0)
Non-Hispanic Caucasian (%) 1 (7) 5 (36) 0.1186#
Black (%) 13 (87) 9 (64)
Chemokine score, median (range) 93 (87–100) 31 (18–40) < 0.0001
Table 1.  Demographics of individuals with SLE analyzed by GMR biosensor autoantigen microarrays. 
Groups were compared by Mann-Whitney test, or Fisher’s exact test (indicated by #).
www.nature.com/scientificreports/
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individual in the low chemokine score group, so we focused on the other autoantigens. To our knowledge, the 
other 12 autoantibodies identified by SAM have not previously been associated with chemokine scores. They 
included histones (H2A and H4, H2B, and H3), methylated (K5Me1, K5Me2 and K11Me2) and unmodified 
peptides from the N-terminal tail of H2B, Ribo P, Sm, Ro60, and U1-70K.
Validation of autoantibody associations with dysregulation of the IFN pathway by ELISA. To 
confirm the association of anti-U1-70K with chemokine scores observed by the microarray, we performed ELISA 
with sera from an independent set of SLE patients in the ABCoN cohort with high (n = 24) and low (n = 20) 
chemokine scores. In agreement with the GMR biosensor autoantigen microarray, we found that individuals with 
high chemokine scores had higher levels of serum IgG antibodies to U1-70K, than those with low chemokine 
scores (Fig. 4).
To confirm the association of antibodies to methylated and unmodified peptides from the N-terminal tail of 
histone H2B with dysregulation of the IFN pathway, we performed peptide ELISA with an independent cohort of 
SLE patients with high (n = 15) and low (n = 15) IFN signatures. The sera of 15 healthy controls were measured in 
parallel. We selected acetylated, dimethylated and unmodified versions of H2B 1-7 and H2B 8-14 for the ELISA. 
Similar to observations with the microarrays (Fig. 3 and Supplementary Figure 7), we found that SLE patients 
with high chemokine scores had greater serum IgG reactivity to unmodified and dimethylated (K11Me2) forms 
of the H2B peptides, compared to patients with low chemokine scores (Fig. 5). While the difference in reactivity 
to K5Me2 between SLE patients with high and low IFN signatures did not reach statistical significance by ELISA, 
there was still a strong trend toward greater reactivity in patients who had high IFN signatures. These findings 
demonstrate that GMR biosensor autoantigen microarrays are capable of identifying autoantibodies associated 
with dysregulation of the IFN pathway, and defining clinically relevant patient subsets in SLE.
Discussion
In this study, we developed GMR biosensor autoantigen microarrays and used them to identify autoantibodies 
associated with chemokine scores and dysregulation of the IFN pathway in SLE. The microarrays were based on 
GMR biosensor chips, which are capable of measuring local magnetic field changes induced by the presence of 
MNPs at 72 effective sensors in real time. We validated the microarrays using monoclonal and polyclonal anti-
bodies, and found that the microarrays were capable of sensitive and specific detection of antibodies to recombi-
nant human autoantigens, antigenic peptides, and post-translationally modified peptides corresponding to the 
N-terminal tail of histone H2B. Real-time measurement of antibody reactivity to post-translational modifications 
(PTMs) and their consensus binding sequences, as well as point mutants, with GMR biosensor microarrays could 
allow rapid screening and characterization of hybridomas or cloned antibody libraries.
Previous studies have found associations between IFN gene scores and the presence of specific autoantibodies 
in SLE4,19–25. However, there was variation in the associations between studies, potentially related to differences 
between patient groups, and the methods used to determine the IFN gene scores and measure antibodies. The 
autoantibodies associated with chemokine score in SLE are likely more clinically relevant, as chemokine scores 
were more highly correlated with SLE disease activity, as measured by SLE disease activity index (SLEDAI), 
Figure 3. GMR biosensor autoantigen microarrays identify autoantibodies associated with dysregulation 
of the IFN pathway in SLE. Serum samples from SLE patients with high (n = 15) or low (n = 15) chemokine 
scores were evaluated using GMR biosensor autoantigen microarrays. A single microarray was used to measure 
each sample. Significance analysis of microarrays (SAM) was used to identify autoantigens with significantly 
different antibody reactivity between the groups (q < 0.001, Wilcoxon). An unsupervised hierarchically 
clustered heatmap (Euclidean distance, complete linkage) shows the candidate autoantigens identified by SAM.
www.nature.com/scientificreports/
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systemic lupus activity measure-revised (SLAM-R), erythrocyte sedimentation rate (ESR), and anti-DNA, than 
the IFN gene score5. Further, chemokine score was found to be predictive of disease flare in SLE6, while IFN gene 
score was not20. To date, only anti-dsDNA has been associated with chemokine score in SLE5,6.
To identify autoantibodies associated with chemokine scores and dysregulation of the IFN pathway in SLE, we 
used GMR biosensor autoantigen microarrays to compare sera from individuals with SLE who had high or low 
chemokine scores. The microarray analysis revealed that antibody reactivity to 13 autoantigens and peptides was 
significantly greater in individuals with high chemokine scores, compared to those with low chemokine scores, 
including histones (H2A and H4, H2B, and H3), methylated and unmodified peptides from the N-terminal tail 
of H2B, Ribo P, Smith, Ro60, and U1-70K. To our knowledge, these associations were novel and have not been 
reported previously. We confirmed the association of high chemokine scores with serum reactivity to U1-70K in 
an independent cohort of individuals with SLE by indirect ELISA. This was in agreement with previous studies 
Figure 4. Antibodies to U1-70K are associated with high chemokine scores in SLE. Serum samples from SLE 
patients with high (n = 24; red) and low (n = 20; blue) chemokine scores were assessed for IgG reactivity to U1-70K 
by indirect ELISA. P-value was determined using a Mann-Whitney test. Bars represent medians.
Figure 5. Antibodies to post-translationally modified forms of the H2B N-terminal tail are associated 
with dysregulation of the IFN pathway. Sera from SLE patients with high (n = 15) and low (n = 15) IFN 
signatures as well as healthy controls (n = 15) were analyzed for IgG reactivity to peptides from the N-terminal 
tail of histone H2B by indirect ELISA. The peptides corresponded to acetylated (blue), dimethylated (red) and 
unmodified (black) forms of H2B 1-7 (a) and H2B 8-14 (b). P-values were determined using Mann-Whitney 
tests. Bars represent medians.
www.nature.com/scientificreports/
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that found anti-RNP was associated with increased IFN gene scores19,22,23, and provides more detail as to the spe-
cific subunits of the U1-RNP complex that are targeted in the context of dysregulated IFN signaling.
Similar to U1-70K, a number of the other autoantibody associations we observed paralleled previous studies 
on IFN gene scores in SLE, including dsDNA4,20,22,23,25, Smith19,20,22, Ribo P19, and specific histone proteins (H1, 
H2A, H2B, and H3/H4)24, further confirming their association with dysregulated IFN signaling. Two previous 
studies found anti-Ro19,22 was associated with increased IFN gene scores, while another did not23. Most clinical 
tests for Ro antibodies use a combination of two antigens, Ro60 and Ro52, despite the fact that patient sera may 
have reactivity to either or both of the antigens, and that individual measurement provides clinical informa-
tion26,27. Interestingly, we found that SLE patients with high chemokine scores had significantly greater reactivity 
to Ro60, but not Ro52, compared to patients with low chemokine scores. La antibodies are often observed in 
combination with anti-Ro in SLE. In agreement with Nikpour et al.23, and counter to Li et al.’s19 findings with the 
IFN gene score, we did not observe a significant association between high chemokine scores and reactivity to La.
The N-terminal tail of H2B is a known autoantigen in SLE8,24 and PTMs of the tail are involved in regulation 
of chromatin structure and gene expression28,29. The GMR biosensor autoantigen microarrays identified novel 
associations between chemokine scores and serum reactivity to methylated (K5Me1, K5Me2 and K11Me2) and 
unmodified peptides from the N-terminal tail of H2B in individuals with SLE. ELISA measurements with an 
independent cohort of SLE patients with high or low IFN signatures demonstrated that serum IgG reactivity to 
unmodified and dimethylated forms of the H2B N-terminal tail are associated with dysregulation of IFN signal-
ing. Post-translational modifications have been proposed as a mechanism of loss of tolerance to self-antigens30,31. 
Further, distinct histone tail modifications are enriched in neutrophil extracellular traps (NETs), a potential 
self-antigen present at sites of inflammation32. Our results suggest that tolerance has been broken to the dimeth-
ylated form of the N-terminal tail of H2B. It will be interesting to investigate whether this histone mark is also 
enriched in NETs.
Limitations of the GMR biosensor autoantigen microarray platform include the number of GMR biosen-
sors on each chip and the technique’s sensitivity. As GMR biosensors are highly scalable (over 100,000 sensors 
per cm2)15,33, additional sensors will be included on future generations of the chips, increasing the number of 
autoantigens that can be measured in parallel. Compared to previous use of GMR microarrays to measure soluble 
proteins using matched capture and detection antibody pairs, the GMR biosensor autoantigen microarrays had 
lower sensitivity (comparable to ELISA). We are currently investigating immobilization chemistry and blocking 
as potential factors influencing the technique’s sensitivity.
Advantages of GMR biosensor autoantigen microarrays include that they could be easily adapted to detect 
autoantibodies in other clinical applications, including additional autoimmune diseases or cancer34. Further, 
GMR biosensors can measure antibody binding in real time, allowing the estimation of the affinity of autoanti-
bodies, and longitudinal studies on autoantibody affinity maturation. Our group is currently developing microflu-
idic devices for the GMR biosensor microarrays that will enable precise sample handling35,36, which will enhance 
precision and streamline affinity studies. Additionally, the microarrays could enable point-of-care (POC) meas-
urement of clinically important antibodies, because the reader station can be easily miniaturized to the size of a 
smartphone, and measurements can be performed in minutes.
In conclusion, we have developed GMR biosensor autoantigen microarrays and used them to identify novel 
autoantibody associations with chemokine scores and dysregulation of IFN signaling in SLE. The autoantigens 
included post-translationally modified histone H2B N-terminal tail peptides. Identifying autoantibodies associ-
ated with dysregulation of the IFN pathway in SLE may provide new insights into the mechanisms underlying 
activation of the IFN pathway and SLE pathogenesis. Further, these findings have the potential to inform ongoing 
clinical trials of inhibitors of type I IFN signaling in SLE (ClinicalTrials.gov, NCT02446899 & NCT02446912). 
Future generations of the microarrays have the potential to be real-time clinical proteomics platforms, enabling 
rapid monitoring of disease activity and prediction of disease flares, allowing preemptive treatment.
Methods
Patients. Serum samples from individuals with SLE and normal controls were collected as part of the 
Autoimmune Biomarkers Collaborative Network (ABCoN). The protocols were approved by the University of 
Minnesota Institutional Review Board (protocol 0110M09982), and the samples were studied in accordance with 
the approved guidelines. All individuals with SLE met American College of Rheumatology (ACR) revised criteria 
for classification of SLE37. Written informed consent was obtained from all participants. The chemokine scores of 
all individuals with SLE had been determined, as previously described6.
GMR biosensor chip. An 8 × 10 array of GMR biosensors was fabricated on a chip with a dimension of 
10 × 12 mm (designed by MagArray Inc., CA, USA). Each GMR biosensor consists of multiple stripes of spin 
valve stack of IrMn/CoFe/Ru/CoFe/Cu/CoFe, and has an area of 100 × 100 μ m. The sensors were connected 
through 300-nm-thick Ta/Au/Ta films in the manner of grid network to electrical pads for external connection 
with the reader station. A 30-nm-thick passivation layer was deposited on top of the sensors except 8 sensors in 
the last row, and a 300-nm-thick oxide layer was deposited on the rest of the sensor chip surface to prevent the 
sensors from corrosion and breakdown. The 8 sensors with the thicker passivation layer were used as electrical 
reference sensors.
The reader station equipped with a Helmholtz coil generates an AC magnetic field at a frequency of 90 Hz 
to modulate the magnetization of the sensors. The station also applies an AC current at a frequency of 500 Hz 
through the sensors to operate them using the double modulation scheme38. The details of surface chemistry were 
described in the previous study39.
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GMR biosensor autoantigen microarrays. The autoantigens shown in Supplementary Table 1 were 
printed at 0.2 mg/mL (in PBS) on the sensors of a GMR sensor chip in replicates of 4 using a non-contact microar-
rayer (sciFLEXARRAYER, Scienion, NJ, USA). BSA (Sigma-Aldrich) and biotin-BSA (Fisher Scientific) were 
printed in parallel as quality controls. After printing, the microarrays were incubated overnight in a humid cham-
ber at 4 °C, washed with rinsing buffer (PBS pH 7.4 with 0.1% BSA and 0.05% Tween-20, Sigma-Aldrich), and 
blocked with 1% BSA for 1 hour. After blocking, the microarrays were washed with rinsing buffer and probed 
with diluted serum (1/200 in rinsing buffer) or commercial antibodies for 2 hours (at specified concentrations in 
rinsing buffer) with agitation at room temperature. Commercial antibodies were as follows, anti-FLAG (F1804, 
Sigma-Aldrich), anti-U1-70K (70R-4901, Fitzgerald Industries International), anti-Ro52 (sc-25351, Santa Cruz 
Biotechnology), anti-H2B K5Ac (ab61227, Abcam) and anti-H2B K20Ac (ab52988, Abcam). The microarrays 
were then washed with rinsing buffer and incubated for 1 hour with biotinylated anti-human IgG (109-065-098, 
Jackson ImmunoResearch, PA, USA; at 100 ng/mL), anti-mouse IgG (ab98711, Abcam, MA, USA; at 50 ng/mL), 
or anti-rabbit IgG (ab97198, Abcam; 100 ng/mL) secondary antibodies.
For analysis of serum samples with peptides, streptavidin (5 mg/mL in PBS) was printed on the sensors of 
a GMR sensor chip, along with BSA and purified human IgG (Sigma) controls. After printing, the microarrays 
were incubated overnight in a humidified chamber at 4 °C, washed with rinsing buffer, blocked with 1% BSA 
for 1 hour, and washed sequentially with the rinsing buffer and distilled water. The biotinylated peptides shown 
in Supplementary Table 2 were then printed on the streptavidin-coated sensors using the microarrayer, and the 
microarrays were incubated overnight in a humid chamber at 4 °C. After washing with rinsing buffer, the microar-
rays were probed with diluted serum (1/200 in rinsing buffer) for 1 hour with agitation at room temperature.
Detection of MNPs. Autoantigen microarrays were washed with rinsing buffer and inserted into the reader 
station. The reader station measured the initial magnetoresistive ratio (MR), which is determined by electrical 
resistance changes due to an external magnetic field with respect to the nominal resistance, and recorded the 
baseline signals of each sensor (Supplementary Figure 8). The signals were calculated using a ratio of instantane-
ous MR to the initial MR. After baseline recording, signals from the sensors were recorded during the addition 
of 40 μ L of streptavidin-coated or Protein G-coated MNPs (130-048-101 and 130-071-101, Miltenyi Biotec, CA, 
USA). The stray field from bound MNPs changes the magnetic properties of the sensors and induces changes in 
MR. The signals from BSA- and MCC-coated sensors were considered background of autoantigens and peptides, 
respectively, and were subtracted from all other sensors’ signals on the microarrays. The electrical read-out system 
and methodologies were used according to Hall et al.38.
ELISA. Nunc-Immuno Maxisorp 96-well plates (Thermo Scientific) were coated with U1-70K at 2 μ g/mL in 
PBS (autoantigen information is shown in Supplementary Table 1). A BSA-coated plate (10 mg/mL) was used 
to measure non-specific binding. For biotinylated H2B peptides, Streptavidin High Binding Capacity Coated 
96-Well Plates (Pierce) were coated with the peptides at 2 μ g/mL in PBS. The plates were washed 5 times in wash 
buffer (PBS with 0.05% Tween-20), before blocking with 10 mg/mL BSA in PBS with 0.05% Tween-20. After 
washing, patient sera were diluted 1/100 or commercial antibodies were diluted at the indicated concentrations in 
antibody buffer (10 mg/mL BSA in PBS with 0.05% Tween-20) and incubated overnight at 4 °C. All samples were 
measured in duplicate wells. After washing, plates were probed with Europium conjugated goat-anti rabbit, rabbit 
anti-mouse, or mouse anti-human IgG antibodies (Perkin Elmer AD0105, AD0124 and 1244-330) diluted 1/500 
in Delfia Assay Buffer (Perkin Elmer). Plates were washed and incubated in Delfia enhancement buffer (Perkin 
Elmer) for 25 minutes at 37 °C before measuring the time-resolved fluorescence with a Wallac Victor model 1420 
Multilabel Counter (Perkin Elmer).
Statistics. The R programming language (version 3.2.2) was used for analysis40. The samr package41 was 
used for SAM analysis with the following settings: nperms = 1000, resp.type = “Two class unpaired”, testStatis-
tic = “wilcoxon” and random.seed = 839938. The pheatmap package was used to render heatmaps42. Prism 6 soft-
ware (GraphPad, La Jolla, CA) was used to perform Mann-Whitney tests (no correction was made for multiple 
testing).
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